**Current Price and Recent Performance**
- As of the latest available data, Max Healthcare Institute Ltd (MAXHEALTH) is trading around ₹1,084.40, showing a 0.64% increase in the past 24 hours
- The stock hit a high of ₹1,095.00 and a low of ₹1,066.50 in the most recent trading session, with an average traded price of ₹1,075.13
- Over the past week, the stock is down by 0.97%, but it has risen 8.23% over the past month and 30.78% over the last year
**Historical Price Levels**
- MAXHEALTH reached its all-time high of ₹1,227.95 on January 8, 2025
- The all-time low was ₹97.15, recorded on November 12, 2020
**Analyst Forecasts and Valuation**
- Analyst price targets range from a minimum of ₹615.00 to a maximum of ₹1,390.00
- The stock is trading at a price-to-earnings (PE) ratio of 100.12 and a price-to-book (PB) ratio of 12.59, which is higher than the sector averages (sector PE: 47.87, sector PB: 6.12)
- Dividend yield is low at 0.14%
**Technical and Volatility Insights**
- MAXHEALTH is 2.61 times as volatile as the Nifty index, indicating higher price swings.
- The 50-day moving average (DMA) is at ₹1,062, suggesting the current price is above this technical support level.
MAXHEALTH's valuation is high compared to peers, reflecting strong investor expectations
**Fundamental Performance**
- Revenue has grown at a compound annual rate of 27.47% over the last five years, outpacing the industry average of 10.01%
- Net profit for FY 2023-24 was ₹687 crore, with a slight decline of 1.02% compared to the previous year, despite a 22.93% rise in revenue.
- Promoter and institutional holdings have remained stable in recent quarters
**Summary**
MAXHEALTH has demonstrated robust long-term price appreciation and revenue growth, with a recent pullback from its all-time high. The stock trades at a premium valuation relative to sector peers, reflecting high growth expectations. Technicals show the stock is above key moving averages, and volatility remains elevated. Analyst targets suggest a broad range of possible outcomes, with the consensus leaning toward further upside, but caution is warranted due to the high valuation and recent profit stagnation
- As of the latest available data, Max Healthcare Institute Ltd (MAXHEALTH) is trading around ₹1,084.40, showing a 0.64% increase in the past 24 hours
- The stock hit a high of ₹1,095.00 and a low of ₹1,066.50 in the most recent trading session, with an average traded price of ₹1,075.13
- Over the past week, the stock is down by 0.97%, but it has risen 8.23% over the past month and 30.78% over the last year
**Historical Price Levels**
- MAXHEALTH reached its all-time high of ₹1,227.95 on January 8, 2025
- The all-time low was ₹97.15, recorded on November 12, 2020
**Analyst Forecasts and Valuation**
- Analyst price targets range from a minimum of ₹615.00 to a maximum of ₹1,390.00
- The stock is trading at a price-to-earnings (PE) ratio of 100.12 and a price-to-book (PB) ratio of 12.59, which is higher than the sector averages (sector PE: 47.87, sector PB: 6.12)
- Dividend yield is low at 0.14%
**Technical and Volatility Insights**
- MAXHEALTH is 2.61 times as volatile as the Nifty index, indicating higher price swings.
- The 50-day moving average (DMA) is at ₹1,062, suggesting the current price is above this technical support level.
MAXHEALTH's valuation is high compared to peers, reflecting strong investor expectations
**Fundamental Performance**
- Revenue has grown at a compound annual rate of 27.47% over the last five years, outpacing the industry average of 10.01%
- Net profit for FY 2023-24 was ₹687 crore, with a slight decline of 1.02% compared to the previous year, despite a 22.93% rise in revenue.
- Promoter and institutional holdings have remained stable in recent quarters
**Summary**
MAXHEALTH has demonstrated robust long-term price appreciation and revenue growth, with a recent pullback from its all-time high. The stock trades at a premium valuation relative to sector peers, reflecting high growth expectations. Technicals show the stock is above key moving averages, and volatility remains elevated. Analyst targets suggest a broad range of possible outcomes, with the consensus leaning toward further upside, but caution is warranted due to the high valuation and recent profit stagnation
면책사항
이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.
면책사항
이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.